Treatment of Glioblastoma (GBM) with the Addition of Tumor-Treating Fields (TTF): A Review.
Publication/Presentation Date
2-2-2019
Abstract
Glioblastoma (GBM) is the most common primary brain tumor. Despite aggressive treatment, GBM almost always recurs. The current standard-of-care for treatment of newly diagnosed GBM has remained relatively unchanged since 2005: maximal safe resection followed by concomitant chemoradiation (CRT) with temozolomide (TMZ), and subsequent adjuvant TMZ. In 2011, the first-generation tumor treating fields (TTF) device, known at the time as the NovoTTF-100A System (renamed Optune), was approved by the Food and Drug Administration (FDA) for treatment of recurrent GBM. The TTF device was subsequently approved as an adjuvant therapy for newly-diagnosed GBM in 2015. The following is a review of the TTF device, including evidence supporting its use and limitations.
Volume
11
Issue
2
ISSN
2072-6694
Published In/Presented At
Fabian, D., Guillermo Prieto Eibl, M. D. P., Alnahhas, I., Sebastian, N., Giglio, P., Puduvalli, V., Gonzalez, J., & Palmer, J. D. (2019). Treatment of Glioblastoma (GBM) with the Addition of Tumor-Treating Fields (TTF): A Review. Cancers, 11(2), 174. https://doi.org/10.3390/cancers11020174
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
30717372
Department(s)
Administration and Leadership
Document Type
Article